Dendreon to Cut 15% of Jobs as Provenge Sales Disappoint

Dendreon Corp. plans to cut 150 jobs, or about 15 percent of its workforce, to trim operating expenses after sales of its prostate-cancer drug Provenge missed analysts’ estimates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.